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ABSTRACT 
Objective: Silybum marianum L. Food Supplements that contain silymarin is widely used as a therapeutic agent in liver diseases. Many brands are available 
on the market in USA, Egypt, Europe and other countries. The objective of this study was to compare the biological activity in different preparations of 
silymarin available on the market in USA and Egypt using paracetamol-induced oxidative stress injury on primary cultured rat hepatocytes.  
Methods: Forty four silymarin samples available on the market were collected from USA (24) and Egypt (20) and tested for hepat protective 
antioxidant effects on primary cultured rat hepatocytes. Cytotoxicity was measured by MTT [3-(4, 5-dimethyl-thiazol-2)-2,5-diphenyl tetrazolium 
bromide] assay and lactate dehydrogenase (LD) leakage into culture medium. Antioxidant effects were determined by glutathione reductase (GR), 
and Nitric oxide (NO) assays in silymarin, pretreated rat hepatocytes for 2 h followed by incubation with 25 mM paracetamol over a period of 1 h. 
Therapeutic index was calculated for each tested sample for comparative analysis.  
Results: Silymarin preparations significantly decreased toxicity induced by paracetamol in rat hepatocytes, decreased lactate dehydrogenase 
leakage and prevented GSH depletion (P<0.01) and returned NO to basal levels in rat hepatocytes. The therapeutic index was 80, 40 and 20 for 
samples No. 20, 19 and 5 respectively.  
Conclusions: The 44 different silymarin preparations tested in this study exhibited variation in antioxidant capacity and in reducing nitric oxide produced 
as a result of paracetamol injury. This variation in biological activity did not always correspond to the amount of silymarin recorded on samples. 
Keywords: Silymarin, Primary Cultured Rat Hepatocytes, Antioxidant Effect, Glutathione Reductase, Nitric Oxide. 
 
INTRODUCTION 
Silybum marianum L. (SM), commonly called milk thistle, is an 
annual or biennial plant that is native to the Mediterranean and 
North Africa but has spread to other warm and dry climates in North 
America, Australia, and Europe. The seed extract of SM is expressed 
as total silymarin, the active principle, which is approximately 60 % 
of dried extracts of milk thistle seeds [1, 2]. Traditional medicines, 
including medicinal herbs and their preparations, are used as part of the 
primary health care for 70-95 % of the population in the developing 
world, while over 70 % of the population in developed nations use some 
form of complementary/alternative medicines [3]. The last few decades 
have witnessed therapeutic benefits of milk thistle and silymarin in liver 
necro inflammation and fibrosis given its free-radical scavenging, 
antioxidant, anti-inflammatory, immunomodulatory, iron chelating, and 
membrane stabilizing properties as well as its ability to selectively 
stimulate hepatocyte proliferation [4]. Moreover, being a natural remedy 
for liver diseases and its entry into NIH clinical trial signifies its 
hepatoprotective potential [5]. 
Silymarin is noted for its ability to interfere with apoptotic signaling 
while acting as an antioxidant [6]. The German Commission E 
recommends silymarin for the treatment of dyspeptic complaints, 
toxin-induced liver damage, and hepatic cirrhosis and as a supportive 
therapy for chronic inflammatory liver conditions [7]. Recently, a 
systematic review has reported the efficacy and safety of milk thistle 
products in alcohol, viral or toxin-related liver diseases [8]. 
Many sole and combined products of silymarin with well-defined 
preparations are sold under more than 50 different brand names 
and available market. Silymarin was among the 5 top selling herbal 
supplements of 2011 in the health and natural foods channel, 
according to SPINS. Sales of milk thistle in the USA were $108 
million in 2011, up 10.2 % from the prior year according to the latest 
fig. from Nutrition Business Journal [9]. 
Silymarin is a potent antioxidant composed of several flavolignans. 
Antioxidants or free radical scavengers are very important in 
protecting the living cells against any damage, induced by free 
radicals which are produced continuously in cells, either during 
phagocytosis or accidentally as by-product metabolites. Each 
biological system has certain antioxidant mechanisms against the 
aggregations of such free radicals. The balance of oxidant-
antioxidant system must exist in the cell while the disturbance of 
antioxidant-prooxidant balance causes oxidative stress [10]. 
Antioxidants are an important endogenous defense mechanism 
against injury caused by lipid peroxidation and harmful reactions, 
induced by reactive oxygen species (ROS), which are constantly 
produced in the body during normal metabolic processes [11]. 
Antioxidants may act individually or in synergy. Many antioxidant 
enzymes are sequestered in peroxisomes. Repair mechanisms are 
also available in the cells as potent mechanisms for removal of 
oxidized membrane fatty acids [12]. 
In vitro liver systems represent a convenient system to study screen 
and compare potential hepatotoxic compounds and to investigate 
the mechanism by which chemicals induce liver lesions [11]. The 
best and most successfully applied in vitro models are primary 
cultured mouse/rat. 
Hepatocytes, which generally reproduce the in vivo pathophysiology 
[13, 14]. In contrast to intact rats, dose-dependent glutathione 
depletion, oxidant stress and cytotoxicity (necrosis) have also been 
shown in cultured rat hepatocytes [15]. Paracetamol 
(Acetaminophen) has been used extensively during the last 40 y as a 
model toxicant, which allows investigation of drug induced cell 
death in vivo and in vitro. Many basic concepts of drug toxicity were 
developed using this model. As a consequence, paracetamol toxicity 
is one of the most popular models to test potentially 
hepatoprotective agent’s especially natural products [16].  
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Paracetamol is mainly metabolized in liver to excretable glucuronide 
and sulfate conjugates. However, the hepatotoxicity of paracetamol 
has been attributed to the formation of toxic metabolites when a 
part of paracetamol is activated by hepatic cytochrome P-4 50 to a 
highly reactive metabolite N-acetyl-p-benzoquinoneimine (NAPQI) 
[17]. During the detoxification process, glutathione is, directly or 
indirectly, consumed with subsequent hepatic necrosis. Nitric oxide 
(NO) is very specific to liver injury and is almost always produced 
during liver inflammation. Downregulation, NO production is 
considered to be an indicator of liver protection [18]. Up to the time 
of writing this study, no published reports were available regarding 
the comparative analysis of silybum marianum food supplements 
present on market. Therefore, we aimed to compare equal weights 
of SM food supplements of commercially available brands sold in 
USA and Egypt for cytotoxicity, hepatoprotection, antioxidant 
activity and therapeutic index on primary cultured rat hepatocytes. 
MATERIALS AND METHODS 
Chemicals and reagents 
All solvents used for extraction were of chromatographic grade, 
dimethyl sulfoxide (DMSO) was purchased from Merck. Technical 
silymarin (>96 % pure) and quercetin were purchased from Sigma 
Aldrich Inc., and kits were purchased from Biodiagnostic Co., Egypt. 
All commercial over-the-counter milk thistle food supplements 
samples were obtained from USA and Egyptian markets. Samples 
identification numbers, sources and brand names are shown in 
(table 1). 
Preparation of samples 
Ten tablets of each commercial sample were randomly taken, 
crushed and homogenized. Tablets in the form of coated capsules 
were freed from the capsules cover and their content was 
homogenized as above. Weight of each 10 tablets was recorded and 
is presented for each brand sample in (table 1). Twenty mg of each 
product were extracted in 5 ml of methanol. 
Isolation and preparation of rat hepatocytes monolayer culture 
A primary culture of rat hepatocytes was prepared according to 
Seglen, 1976 method [19] and modified by Kiso et al., 1983 [20] 
using Wistar male rats (250-300 g) obtained from the animal house 
of the NRC (National Research Center, Cairo). Animal procedures 
were performed in accordance with the Ethics Committee of the 
National Research Centre and followed the recommendations of the 
National Institutes of Health Guide for Care and Use of Laboratory 
Animals (NIH Guide, 1985) [21]. 
LD50 determination on rat hepatocytes monolayer culture 
In order to determine LC50, different concentrations were prepared 
for each sample (100–1000 μg/ml). After two hours incubation of 
cells with the extract, cell viability was determined using the MTT 
assay. The assay was performed according to the method of 
Mosmann, 1983 [22] modified by Carmichael et al., [23]. Absorbance 
of formasan crystals produced by viable cells was read at 540 and 
630 nm dual wave-length using the Automatic Kinetic Microplate 
Reader (Lab Systems Multiskan RC Reader). Each experiment was 
repeated three times and the mean absorption of each concentration 
was calculated.  
Lactate dehydrogenate (LDH) leakage 
After cell treatment mentioned above, LDH leakage from cell cytosol 
to the culture medium was measured in culture medium to reflect 
cell viability. The LDH leakage was measured by an optimized 
standard method according to the method of King [24]. 
Evaluation of hepatoprotective activity 
The primary culture of rat hepatocytes monolayer was treated with 
different concentrations (12.5, 25, 50, 100 μg/ml) using serial 
dilutions technique by dissolving in DMSO (1 % maximum 
concentration). For each concentration, three replicates were 
carried out; in addition to a positive control that was 50 μg/ml 
Silymarin (madawas). The plate was incubated for 2 h at 37 °C and 5 
% CO2, then washed twice with PBS. Two hundreds μl of 25 mM 
paracetamol was added to each well. After one hour incubation with 
the paracetamol, cell viability was determined using the MTT assay. 
The concentration of the extract that was able to protect the cells 
from the hepatotoxic effect of paracetamol by 100 % was considered 
hepatoprotective. In animal studies, the therapeutic index is the 
lethal dose of a drug for 50 % of the population (LD50) divided by 
the minimum effective dose for the population (ED). 
Glutathione reductase (GR) assay 
The content of reduced glutathione was assayed by the 
spectrophotometric method of Goldberg and Spooner [25]. The assay 
was performed by using 5, 5′ -dithiobis-2-nitrobenzoic acid (DTNB), 
which reacts with oxidized glutathione reductase (GSH) to form a 
product (GSSG) with a maximum absorbance at 412 nm. The reduction 
in GSSG level was determined by reducing GSSG into GSH by adding 
glutathione reductase and nicotinamide adenine dinucleotide 
phosphate (NADPH). The resulting GSH was reacted with DTNB. A 
standard curve of GSH in the culture medium was constructed with 
concentrations of GSH ranging from 0–100 μM. Glutathione reductase 
activity was expressed as units of enzyme per 106
Different preparations of SM food supplements investigated in this 
study revealed little toxic effect on primary culture of rat 
hepatocytes as assessed by MTT assay. Cell viability was maintained 
at above 98 % in all preparations up to 25 μg/ml. When the cells 
were exposed to silymarin preparations at concentration of 50 
μg/ml, 14 samples out of 44 revealed reduced cell viability to 67.3 
%±2.8. Whereas, the remaining 30 samples started to induce toxic 
effect at a concentration of 100 μg/ml as indicated by reduced cell 
viability to 59.7 %±5.7. Cytotoxicity results obtained by MTT assay 
coincided with results obtained by LDH leakage into the culture 
medium of rat hepatocytes. Experiments of hepatoprotection effect 
against paracetamol revealed dose dependent protection. Thirty 
three samples exerted hepatoprotection against paracetamol at low 
concentration of 12.5 μg/ml, while 7 samples exhibited 
hepatoprotection at concentration of 25 μg/ml. The remaining 4 
samples showed hepatoprotection at concentration of 50 μg/ml. No 
toxic effects were noticed either by morphological changes of cells or 
by LDH leakage into the culture medium at the concentrations that 
showed hepatoprotection. Calculations of the therapeutic index of 
the different samples investigated are shown in (table 2). Samples 
labeled with numbers: 5, 11, 15, 17, 25, 28, 29, 30, 31, 32, 33, 35, 36, 
37, 38, 39, 40, 41, 43 and 44 showed the highest therapeutic index of 
80 that was similar to that of quercetin. Four of which from USA 
market and 16 samples were commercially sold in the Egyptian 
market. Samples labeled with numbers: 4, 6, 12, 14, 16 showed the 
least therapeutic index of 20. While the remaining samples showed 
therapeutic index in the middle of value of 40 (samples: 1, 2, 3, 7, 8, 
9, 10, 13, 18, 19,20, 21, 22, 23, 24, 26, 27, 34 and 42). Fig. 1 
represents results of MTT assay in four samples (5, 11, 15, and 17) 
and quercetin as a reference control. 
 cells. 
Determination of nitric oxide (NO) production 
After cell treatment mentioned above, for evaluation of 
hepatoprotective activity, culture medium was used for 
measurements of nitrite (a stable metabolite of NO) to reflect NO 
production by the Griess method [26]. Decrease levels of NO 
production are indicative of hepatoprotection. Quercetin was used 
as a reference control. 
Statistical analysis 
Experiments were repeated at least three times using different 
hepatocyte preparations. The results are expressed as mean±SD. 
After testing of normality, the statistical significance was analyzed 
using one way ANOVA followed by Pearson and Spearman 
nonparametric correlation analysis with two-tailed significance 
determined. Statistical significance was considered when value of p 
was<0.05. Statistical analysis was performed using SPSS, version 13 
(SPSS Inc, Chicago, IL, USA).  
This study was approved by IRB, National Research Centre, Egypt. 
RESULTS AND DISCUSSION 
Hepatoprotective effect against paracetamol 
Hammouda et al. 
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Table 1: Commercial milk thistle samples: (Silymarin) 
S. 
No. 




Sample ID #/Description/Sources & Average weight of each 
tablet 
1 Swanson Superior Herbs
Milk Thistle 80 % Silymarin/USA (0.5504 g/tablet) 
® 25 SEDICO
Silymarin Plus, Dietary Supplement/Egypt 
® 
2 Ortho Molecular Products
Silymarin Forte/USA (0.4502 g/tablet) 
® 26 Hepamarin®
Hepatoprotective/Egypt 
 140 mg 
3 Metabolic Response Modifiers
Silymarin with Bio Sorb/USA (0.4975 g/tablet) 
® 27 Hepacure/Mepaco/Egypt 
 
4 Advance Physician Formulas®
Milk Thistle (Standardize Silymarin 80 %)/USA 
((0.3319 g/tablet) 28 Hepaticum® 
5 
Cyclodextrin enhanced formula/Egypt Liver support, 
Soft gelatin capsules/Egypt 
Pure Encapsulations®
Silymarin Milk Thistle Extract/USA 
(0.2430 g/tablet) 29 Ursoplus®
Silymarin 70 %/Egypt 
MINAPHARM 
6 Thorne Research T. A. P. S









8 Himalaya Liver Care





Milk Thistle (Standardize Silymarin Extract 30:1) 
/USA (0.2786 g/tablet) 33 Liverin








Mega Silymarin with isosilybin B/USA 









Maximum Milk Thistle, SilybinPhytosome 240 mg 
/USA (0.5063 g/tablet) 37 MEPASIL
Silymarin, Liver support/Egypt 
® 
14 Enzymatic Therapy
Super Milk Thistle/USA (0.3262 g/tablet) 
®   
15 Advanced Beta Glucon Therapy®
Bio-Silymarin, Aloha Medicinal Inc./USA 
(0.4867 g/tablet) 38 Livit
Liver support, Soft gelatin capsules/Egypt 
® 
16 Futurebiotics
Silymarin Plus/USA (1.0514 g/tablet) 
® 39 Hepanox®
Napha food support/Egypt 
 Cap. 
17 Planetary Herbals®
Full Spectrum Silymarin 80













200 count Milk Thistle Extract/USA 




Silymarin Plus/USA (0.9847 g/tablet) 




Silymarin 100 V caps/USA (0.5090 g/tablet) 




Milk Thistle Extract 250 mg/USA (0.6765 g/tablet) 
® 45 Quercetin/Sigma 
23 TwinLab
Silymarin/USA (0.1610 g/tablet) 
®   
24 Nature's Bounty®
Milk Thistle1000 mg/USA (0.3939 g/tablet) 













































Fig. 1: Viable cell absorbance showing the hepatoprotective effect of some samples against the hepatotoxic effect of paracetamol (25 mM) 
using MTT assay. Data represents mean of 3 replicates 
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Table 2: Effect of Silymarin Preparations on LDH Leakage, LD50, Initial Effective Dose (ED), Therapeutic index (TI), Glutathione Reductase 
and Nitric Oxide Levels in Culture Medium of Rat Hepatocytes 
Sample  %LDH leakage in culture medium after 2h 

















cells) 125 250 500 1000 
1 19 22 51 78 500 12.5 40 5157.72 11.17±2.2 
2 21 24 61 85 500 12.5 40 5583.06 11.17±2.7 
3 22 26 49 89 500 12.5 40 5062.60 12.83±3.1 
4 18 25 55 97 500 25 20 5721.72 7.47±2.4 
* 17 5 22 31 60 1000 12.5 80 5917.33 3.08±1.7 
6 20 26 29 74 1000 50 20 5147.00 7.67±1.1 
7 19 22 47 94 500 12.5 40 5169.10 6.58±1.6 
8 18 21 29 83 1000 25 40 5195.54 6.42±3.8 
9 17 22 31 78 1000 25 40 5113.52 9.42±0.92 
10 18 24 55 102 500 12.5 40 5240.12 7.92±1.6 
* 18 11 20 27 69 1000 12.5 80 5186.52 7.25±1.8 
12 21 22 24 83 1000 50 20 4915.93 6.58±2.6 
13 19 21 25 79 1000 25 40 4848.92 7.92±2.5 
14 19 22 27 89 1000 50 20 4864.33 4.25±3.1 
* 17 15 22 28 74 1000 12.5 80 4942.70 5.75±1.4 
16 21 24 24 84 1000 50 20 5139.63 7.50±3.3 
* 16 17 22 26 76 1000 12.5 80 4899.83 9.58±1.8 
18 17 22 23 73 1000 25 40 4976.86 6.67±2.4 
19 19 21 53 98 500 12.5 40 5047.86 9.50±0.86 
20 17 21 49 89 500 12.5 40 5222.69 5.42±0.67 
21 17 22 51 105 500 12.5 40 5004.99 6.75±0.47 
22 19 23 47 89 500 12.5 40 5011.02 6.0±0.87 
23 21 23 47 91 500 12.5 40 5013.03 7.0±0.91 
24 21 24 54 97 500 12.5 40 5173.12 4.50±0.68 
25 22 24 26 69 1000 12.5 80 4734.38 12.37±1.9 
26 19 21 58 94 500 12.5 40 5927.30 6.47±2.3 
27 18 20 25 58 1000 25 40 5278.20 6.96±2.1 
28 19 21 26 60 1000 12.5 80 6230.70 6.59±2.3 
29 18 22 27 59 1000 12.5 80 4773.91 10.93±1.7 
30 17 19 22 58 1000 12.5 80 5203.92 118.33±1.1 
31 19 21 23 54 1000 12.5 80 4681.42 6.19±1.6 
32 19 22 24 55 1000 12.5 80 5390.86 6.42±2.8 
33 21 25 26 53 1000 12.5 80 5071.91 11.22±2.33 
34 19 23 29 54 1000 25 40 4836.83 7.93±1.8 
35 19 23 27 48 1000 12.5 80 5141.67 3.07±1.22 
36 22 24 25 55 1000 12.5 80 5060.56 7.07±2.5 
37 21 25 27 57 1000 12.5 80 5016.33 3.26±3.1 
38 21 22 23 59 1000 12.5 80 5035.11 6.22±1.4 
39 19 22 24 62 1000 12.5 80 4896.44 7.96±3.3 
40 18 20 24 48 1000 12.5 80 4891.12 51.10±1.8 
41 17 21 24 49 1000 12.5 80 4834.55 6.96±2.4 
42 19 22 47 89 500 12.5 40 4623.82 5.30±0.86 
43 20 23 26 61 1000 12.5 80 4673.44 4.48±0.67 
44 21 23 25 53 1000 12.5 80 4723.67 5.67±0.47 
* 19 Quercitin 22 24 51 1000 12.5 80 5428.33 5.11±1.7 
 
 
Fig. 2: Activity of glutathione reductase was measured as decreased 
of NADPH absorbance at 340 nm and expressed as Unit enzyme 
activity per 100 cells. The results are expressed as mean, n=3 
 
Fig. 3: Bar chart showing the difference in nitrite activity using 
nitric oxide kit assay of some tested samples. Data represent 
mean of 3 replicates/point 
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Effect of silymarin preparations on glutathione reductase (GR) 
activity 
Data from this study revealed that treatment of hepatocytes with 
paracetamol significantly decreased GR content in the cells 
compared to normal control untreated cells (P<0.01). The decrease 
of GR in the cells resulted from depletion of GR during oxidative 
injury of hepatocytes. 
Pretreatment of hepatocytes with different concentrations of silymarin 
preparations for two hoursprior to the addition of paracetamol to the 
cells provided significant protective effect against this depletion. 
Tested silymarin preparations modulated the liver against oxidative 
stress in a dose dependant manner without any cellular cytotoxic 
changes at treated doses. GR content in the cells of different silymarin 
samples were elevated corresponding to the addition of various 
concentrations of the silymarin preparations. Only few samples 
showed significant difference with the reference control, quercetin as 
shown in (table 2). Fig. 2 represents results of GSH assay in four 
samples (5, 11, 15, and 17) and quercetin as a reference control. 
Effect of silymarin preparations on the inhibition of nitric oxide 
(NO) production 
Pretreatment of hepatocytes with different concentrations of 
silymarin samples for two hours prior to the addition of paracetamol 
to the cells reduced the levels of nitrite, an NO metabolite, inculture 
medium to mean basal levels. Results revealed dose dependent 
decrease in the levels of NO in culture medium of hepatocytes. 
Silymarin preparations showed no cellular cytotoxicity within the 
indicated concentrations, as evaluated by the release of LDH into the 
culture medium and trypan blue exclusion by hepatocytes. Tested 
silymarin samples with numbers: 5, 14, 24, 33, 36 and 42 revealed 
specific injury protection of hepatocytes, as shown by the inhibition 
of NO production. Those silymarin samples exhibited the same effect 
or even better protection exertedby quercetin as shown in (table 2). 
Fig. 3 represents results of NO assay in four samples (5, 11, 15, 17) 
and quercetin as a reference control. 
DISCUSSION 
The fruit of the milk thistle plant (Silybum marianum L., Family 
Asteraceae) contains flavonoids that are proven liver protectants 
and used in the treatment of liver diseases [27-29]. The 
standardized extract known as silymarin contains three flavonoids 
of the flavonol subclass. Silybin predominates, followed by silydianin 
and silychristin [30]. These constituents likely offer the synergistic 
benefit of sparing liver cells from destruction [31]. Silybin protects 
the liver by conserving glutathione, the key antioxidant in the liver, 
in the cell [32]. Although silybin is the most potent of the flavonoids 
in milk thistle, similar to other flavonoids it is not well absorbed [33, 
34]. Several pharmaceutical manufacturers have developed milk 
thistle products standardized to a higher content of silymarin (70 %-
80 %) than in non-standardized herbal preparations [35], mainly 
because of silymarin's poor oral bioavailability [36]. As part of 
pharmaceutical development, several clinical studies have been 
conducted in Europe to assess the efficacy of oral milk thistle 
products in liver diseases of diverse etiology [37]. However, to date 
no comparative analysis of various silymarin brands has been 
reported regarding biological activity or therapeutic index. 
Results from this study revealed effective protection of all tested 
silymarin tablets of hepatocytes from injury-induced paracetamol. 
Although equal weight from each tablet was used for extraction, 
variation was observed among different tablets regarding 
cytotoxicity, antioxidant activity and therapeutic index. The 
therapeutic index (TI) calculated for all tested silymarin 
preparations are far from just being safe as reported for safe drugs 
to have TI between 5 and 10 [38]. The variation observed in 
therapeutic index in different samples may be attributed to various 
concentration of silymarin, variable flavonoids proportions or 
synergistic effect of other food supplements in the same preparation. 
A therapeutic index does not consider drug interactions or 
synergistic effects [39]. Total amounts of silymarin tablets available 
in USA market vary greatly among the different samples with, 1 
sample containing between 100 and 200 mg/g, 3 samples containing 
between 200 and 300 mg/g, 6 samples containing between 300 and 
400 mg/g, 4 samples containing between 400 and 500 mg/g, 4 
samples containing between 500 and 600 mg/g and 6 samples 
containing higher than 600 mg/g as shown in (table 1). The amount 
of silymarin registered on tablets did not always correspond with 
higher biological activity. For example, sample number 5 (from USA 
market), demonstrated the least cytotoxicity, the highest biological 
activity, highest therapeutic index and contained silymarin of only 
0.243g/tablet. Samples number 6 and 16 although had large amount 
of silymarin 0.6789 and 1.0514 g/tablet respectively, revealed the 
least therapeutic index recorded in this study of 20. These findings 
raise the assumption of different flavonol subclass proportions with 
pre dominating the least bioactive isomer. Also the amount of 
silymarin preparations commercially available in Egyptian market 
varies among different samples. Sixteen samples out of 20 showed 
therapeutic index of 80, only 4 samples out of 20 showed 
therapeutic index of 40. Interestingly, sample number 34 from 
(Legalon 70/Germany) demonstrated half the therapeutic index of 
sample number 35 (Legalon 140/Germany) that attributes to 
concentration of silymarin in the preparation. Regarding glutathione 
reductase activity was noticed in all silymarin treated primary rat 
hepatocytes. Three samples showed better results than quercitin. 
Silymarin samples number 2 (0.4502 g/tablet) and 26 (0.140 
g/tablet) although had therapeutic index of 40, lower than other 
samples, they achieved GR activity better than quercitin. Moreover, 
these samples had fewer amount of silymarin than other samples 
and achieved higher GR activity. This raises the assumption of the 
presence of other flavonoids in the same preparation that 
synergistically improved the antioxidant capacity of those samples. 
Sample number 28 had therapeutic index of 80 and showed GR 
activity better than quercitin. The inhibition of NO production was 
detected in all preparations. However, some samples revealed more 
inhibition of NO than others such as sample number 5 which 
contains silymarin of 0.243 g/tablet, although samples with more 
silymarin concentration showed less inhibition of NO production. 
This explains that the variation in activity does not always depends 
on the amount of silymarin in preparations. 
CONCLUSION 
All silymarin preparations investigated in this study revealed 
effective hepatoprotective effect on paracetamol induced liver injury 
through antioxidant mechanism. The variation in LD50, 
hepatoprotective effect, antioxidant activity and therapeutic index 
observed among different samples raise the recommendation to 
standardized isomer quantification and biological activity assays to 
be implemented for evaluation of commercial sources of silymarin. 
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